Moshe Spinowitz is head of Skadden’s Boston office. His tax practice focuses on advising multinational companies in connection with cross-border mergers and acquisitions, and post-acquisition restructuring and integration transactions.
Spinowitz regularly advises multinational companies on the restructuring of their operations, including integration following large cross-border acquisitions. He also counsels pharmaceutical and technology companies in connection with the structuring of their intellectual property holdings, as well as a variety of companies in connection with U.S. and international tax law developments.
Lawdragon Honors
| Honor | Year | Practice |
|---|---|---|
| The 2026 Lawdragon 500 Leading Global Tax Lawyers | 2026 | Tax, Transactional, Controversy |
| The Inaugural Lawdragon 500 Leading Global Tax Lawyers | 2025 | Tax, Transactional, Controversy |
Select representations include:
- Vertex Pharmaceuticals in its $4.9 billion acquisition of Alpine Immune Sciences
- Mirati Therapeutics in its $4.8 billion acquisition by Bristol Myers Squibb
- Dicerna Pharmaceuticals in its $3.3 billion acquisition by Novo Nordisk
- ArQule, Inc. in its $2.7 billion acquisition by a subsidiary of Merck & Co., Inc.
- Gilead Sciences, Inc. in its $11.9 billion acquisition of Kite Pharma, its acquisition of Cell Design Labs for up to $567 million, and its research and development collaboration with, and equity investment in, Galapagos NV
- Konecranes plc in its acquisition of Terex Corporation’s material handling and port solutions unit for $1.28 billion
- Morphosys in its $2.9 billion acquisition by Novartis and simultaneous disposition of Monjuvi to Incyte
- CureVac in its pending $1.25 billion acquisition by BioNTech
- Chimerix in its $935 million acquisition by Jazz Pharmaceuticals
- BioCryst in the sale of its European ORLADEYO business to Neopharmed Gentili for $250 million upfront and up to $14 million in future milestone payments